Albert Bourla, Chairman and Chief Executive Officer of Pfizer, shared a post on LinkedIn:
“Today we announced an agreement to acquire Metsera, a clinical-stage company advancing a promising portfolio of long-acting injectable and oral investigational treatments for obesity and cardiometabolic disease.
This proposed acquisition reflects our strategy to invest where the science is strong and the opportunity for impact is high. Obesity is a serious and growing health challenge, linked to more than 200 conditions and affecting over a billion people globally.
Metsera’s pipeline includes candidates with the potential for best-in-class efficacy, improved tolerability and monthly dosing. By applying Pfizer’s deep cardiometabolic experience and global development, manufacturing and commercial capabilities to the advancement of Metsera’s pipeline, we aim to advance these potential therapies with speed and scale.
Pending satisfaction of customary closing conditions, including receipt of required regulatory approvals and approval by Metsera’s shareholders, we expect the transaction to close in the fourth quarter of 2025.
We’re moving forward with focus and optimism, driven by our colleagues and by our purpose: breakthroughs that change patients’ lives.”
Watch the video attached to this post.
More from Albert Bourla on OncoDaily.